Overview

To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
To investigate the safety and pharmacokinetic properties of CJ-30039 and Lipidil Supra
Phase:
Phase 1
Details
Lead Sponsor:
CJ HealthCare Corporation
HK inno.N Corporation
Treatments:
Fenofibrate
Fenofibric acid